Summary of the Risk Management Plan (RMP) for DUPIXENT®

DUPIXENT® (dupilumab)
Marketing Autorisation Holder : sanofi-aventis (suisse) sa
RMP version 10.3
Date: 25-March-2025

Disclaimer:

The Risk Management Plan (RMP) is a comprehensive document submitted as part of the application dossier for market approval of a medicine. The RMP summary contains information on the medicine's safety profile and explains the measures that are taken in order to further investigate and follow the risks as well as to prevent or minimize them. The RMP summary of DUPIXENT® is a concise document and does not claim to be exhaustive. As the RMP is an international document, the summary might differ from the "Arzneimittelinformation / Information sur le medicament" approved and published in Switzerland, e.g. by mentioning risks occurring in populations or indications not included in the Swiss authorization. Please note that the reference document which is valid and relevant for the effective and safe use of DUPIXENT® in Switzerland is the "Arzneimittelinformation/ Information sur le medicament" (see www.swissmedicinfo.ch) approved and authorized by Swissmedic. Sanofi-aventis (suisse) sa is fully responsible for the accuracy and correctness of the content of this published summary RMP of DUPIXENT®.

I. THE MEDICINE AND WHAT IT IS USED FOR

According to Swiss label

DUPIXENT is indicated for:

Atopic Dermatitis

Dupixent is indicated for the treatment of patients aged 6 months and older with moderate to severe atopic dermatitis whose disease is not adequately controlled with prescription topical therapies or when those therapies are not recommended.

Dupixent can be used with or without topical corticosteroids.

Asthma

Dupixent is indicated in adults and children (aged 6 years and older) as an add-on maintenance treatment for severe asthma meeting the following criteria:

- blood eosinophil count ≥0.15 g/liter (i.e., ≥150 cells/µl), no complete asthma control, and at least 1 severe exacerbation in the previous 12 months, despite treatment combining inhaled corticosteroids and long-acting bronchodilators;

- or necessity for permanent treatment with systemic corticosteroids.

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Dupixent is indicated as an add-on treatment to intranasal corticosteroids in adults with severe chronic rhinosinusitis with nasal polyposis inadequately controlled by systemic corticosteroids and/or surgery.

Prurigo Nodularis (PN)

Dupixent is indicated for the treatment of adults with moderate to severe prurigo nodularis (PN) whose disease is not adequately controlled with prescription topical treatments or when those treatments are not recommended.

Dupixent can be used with or without topical corticosteroids.

Eosinophilic Esophagitis

Dupixent is indicated for the treatment of patients aged 12 years and older and weighing at least 40 kg with eosinophilic esophagitis (EoE), in case of failure, contraindication, or intolerance to conventional drug treatments.

Chronic Obstructive Pulmonary Disease

Dupixent is indicated as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) characterized by high blood eosinophil counts, not controlled by the combination of inhaled corticosteroids (ICS), long-acting beta-2 agonist (LABA), and long-acting muscarinic antagonist (LAMA) or by the LABA/LAMA combination alone if ICS are not suitable.

According to EU-SmPC

DUPIXENT is authorized for:

Atopic dermatitis:

Adults and adolescents

DUPIXENT is indicated for the treatment of moderate-to-severe atopic dermatitis (AD) in adults and adolescents 12 years and older who are candidates for systemic therapy.

Children 6 months to 11 years of age

DUPIXENT is indicated for the treatment of severe AD in children 6 months to 11 years old who are candidates for systemic therapy.

Asthma:

Adults and adolescents

DUPIXENT is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), see section 5.1 of SmPC, who are inadequately controlled with high dose inhaled corticosteroid (ICS) plus another medicinal product for maintenance treatment.

Children 6 to 11 years of age

DUPIXENT is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), see section 5.1 of SmPC, who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.

Chronic rhinosinusitis with nasal polyposis (CRSwNP):

DUPIXENT is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) for whom therapy with systemic corticosteroids (SCSs) and/or surgery do not provide adequate disease control.

Prurigo Nodularis (PN):

DUPIXENT is indicated for the treatment of adults with moderate to severe prurigo nodularis (PN) who are candidates for systemic therapy.

Eosinophilic Esophagitis (EoE):

DUPIXENT is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy (see section 5.1 of SmPC).

Chronic Obstructive Pulmonary Disease (COPD):

DUPIXENT is indicated in adults as add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate (see Section 5.1 of SmPC).

See SmPC for the full indication.

It contains dupilumab as the active substance and it is given by subcutaneous (SC) injection.

Further information about the evaluation of DUPIXENT's benefits can be found in DUPIXENT's EPAR, including in its plain-language summary, available on the European Medicines Agency (EMA) website, under the medicine's webpage:

https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent

II. RISKS ASSOCIATED WITH THE MEDICINE AND ACTIVITIES TO MINIMIZE OR FURTHER CHARACTERIZE THE RISKS

Important risks of DUPIXENT, together with measures to minimize such risks and the proposed studies for learning more about DUPIXENT's risks, are outlined in the next sections.

Measures to minimize the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the PL and SmPC addressed to patients and HCPs;
- Important advice on the medicine's packaging;
- The authorized pack size - the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status - the way a medicine is supplied to the patient (eg, with or without prescription) can help to minimize its risks.

Together, these measures constitute routine risk minimization measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analyzed, including periodic safety update report (PSUR) so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

If important information that may affect the safe use of DUPIXENT is not yet available, it is listed under "missing information" outlined in the next section.

II.A. List of important risks and missing information

Important risks of DUPIXENT are risks that need special risk management activities to further investigate or minimize the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of DUPIXENT. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (eg, on the long-term use of the medicine);

Table 1 - List of important risks and missing information

Important identified risk	Systemic hypersensitivity (including events associated with immunogenicity)
Important potential risk	None
Missing information	Use in pregnant and lactating women
	Long-term safety in paediatric patients

II.B. Summary of important risks

Table 2 - Important identified risk with corresponding risk minimization activities: Systemic hypersensitivity (including events associated with immunogenicity)

Important identified risk: Systemic hypersensitivity (including events associated with immunogenicity)	
Evidence for linking the risk to the medicine	Clinical trial data, literature and postmarketing pharmacovigilance.
Risk factors and risk groups	All patients are at risk of developing systemic hypersensitivity reactions. Risk factors for serum sickness include patient age, dose, duration and the heterologous protein involved in medication. Serum sickness-like reactions are more common in children. Intermittent exposure to a heterologous protein is associated with higher rates of serum sickness-like reactions compared with continuous exposure. [1, 2] Risk factors for anaphylaxis include known hypersensitivity to dupilumab or the excipients in the formulation.
Risk minimization measures	**Routine risk minimization measures:** SmPC sections 4.3, 4.4 and 4.8 PIL sections 2 and 4 Prescription only medicine **Additional risk minimization measures:** None

PIL: Patient Information Leaflet; SmPC: Summary of Product Characteristics.

Table 3 - Missing information with corresponding risk minimization activities and additional pharmacovigilance activities: Use in pregnant and lactating women

Missing information: Use in pregnant and lactating women	
Risk minimization measures	**Routine risk minimization measures:** SmPC sections 4.6 and 5.3 PIL section 2 Prescription only medicine **Additional risk minimization measures:** None
Additional pharmacovigilance activities	**Additional pharmacovigilance activities:** Pregnancy registry study (R668-AD-1639), Pregnancy Outcomes Database Study (R668-AD-1760)

PIL: Patient Information Leaflet; SmPC: Summary of Product Characteristics.

Table 4 - Missing information with corresponding risk minimization activities and additional pharmacovigilance activities: Long-term safety in paediatric patients

Missing information: Long-term safety in paediatric patients	
Risk minimization measures	**Routine risk minimization measures:** Prescription only medicine **Additional risk minimization measures:** None
Additional pharmacovigilance activities	**Additional pharmacovigilance activities:** LTS1434 (R668-AD-1434), and DUPI PEDISTAD registry-based study (CSA0014)

II.C. Post-authorization development plan

II.C.1 Studies which are conditions of the marketing authorization

There are no studies which are conditions of the MA or specific obligation of DUPIXENT.

II.C.2 Other studies in post-authorization development plan

Table 5 - Other studies in post-authorization development plan

Pregnancy registry (R668-AD-1639) (Cat. 3)
Purpose of the study:
To evaluate the effect of exposure to dupilumab on pregnancy and infant outcomes. The study initially included exposed and unexposed cohorts of women with moderate-to-severe AD. The study was amended to include separate exposed and unexposed cohorts of women with asthma. Although there is no specific concern surrounding differential risks of dupilumab exposure for pregnant women with asthma from the clinical trials, the effect of dupilumab on pregnancy outcomes for women with asthma is still considered missing information. Further, the risk of adverse pregnancy outcomes is known to be greater for women with asthma from the general population than for other populations of women. Therefore, it is considered to be of importance to study these outcomes separately to better identify risks that may be associated with dupilumab exposure and asthma. Data from other indications (including CRSwNP, EoE, and PN) will be collected in the “exposure series”.
Pregnancy Outcomes Database Study (R668-AD-1760) (Cat. 3)
Purpose of the study:
To measure the prevalence of adverse pregnancy and infant outcomes in a cohort of women with AD exposed to dupilumab during pregnancy and compare these to each of the two comparator cohorts of pregnant women with AD; one exposed to other systemic medications or phototherapy used for the treatment of AD (never exposed to dupilumab) and the other comprised of women who were not exposed to these treatments during pregnancy.
An open-label extension study to assess the long-term safety of dupilumab in patients ≥6 months to <18 years of age with AD (phase III) (LTS1434) (R668-AD-1434) (Cat. 3)
Purpose of the study:
To assess the long-term safety of dupilumab in pediatric patients with AD.
A registry-based non-interventional post-authorization safety study to evaluate the long-term safety of dupilumab in children aged ≥6 months to <6 years with moderate-to-severe atopic dermatitis (AD) using the PEDISTAD registry: a cohort design (CSA0014) (Cat. 3)
Purpose of the study:
To assess the long-term safety of dupilumab in pediatric patients with AD.

AD: Atopic Dermatitis; CRSwNP: Chronic Rhinosinusitis with Nasal Polyposis; EoE: Eosinophilic Esophagitis; PN: Prurigo Nodularis.

REFERENCES

1. Black RE, Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med. 1980 Oct;69(4):567-70. doi: 10.1016/0002-9343(80)90469-6.

2. Kugathasan S, Levy MB, Saeian K, Vasilopoulos S, Kim JR, Prajapati O, et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol. 2002 Jun;97(6):1408-14. doi:10.1111/j.1572-0241.2002.05784.x.